Cargando…

Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches

Headaches are a very common condition that most people will experience many times during their lives. This article presents the primary headaches, which are a large group of diseases where the headache is not a symptom of another known disease. Tension-type headache affects approximately 80% of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kępczyńska, Katarzyna, Domitrz, Izabela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501363/
https://www.ncbi.nlm.nih.gov/pubmed/36136557
http://dx.doi.org/10.3390/toxins14090619
_version_ 1784795456105086976
author Kępczyńska, Katarzyna
Domitrz, Izabela
author_facet Kępczyńska, Katarzyna
Domitrz, Izabela
author_sort Kępczyńska, Katarzyna
collection PubMed
description Headaches are a very common condition that most people will experience many times during their lives. This article presents the primary headaches, which are a large group of diseases where the headache is not a symptom of another known disease. Tension-type headache affects approximately 80% of the general population, and the prevalence of migraine is estimated at 10–12%. Clinical data and experience to date have demonstrated that botulinum toxin may be an effective prophylactic treatment for chronic headache types. It has been used in neurology for the treatment of dystonia and blepharospasm. Now it has been approved to treat chronic migraine and has been shown to confer significant benefit in refractory cases. Based on clinical experience botulinum toxin has also been tried in other headache disorders. While it is intuitively attractive to think that due to its effect on pain by sensory modulation, there may also be efficacy in its use in chronic tension-type headache and cluster headache, so far, there is little evidence to support this. Botulinum toxin is effective in pain control through its interaction with the SNARE complex, which inhibits the release of neurotransmitters, such as glutamate, substance P and calcitonin gene-related peptide. OnabotulinumtoxinA is effective not only in headache frequency and pain intensity but in other parameters, including quality of life.
format Online
Article
Text
id pubmed-9501363
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95013632022-09-24 Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches Kępczyńska, Katarzyna Domitrz, Izabela Toxins (Basel) Review Headaches are a very common condition that most people will experience many times during their lives. This article presents the primary headaches, which are a large group of diseases where the headache is not a symptom of another known disease. Tension-type headache affects approximately 80% of the general population, and the prevalence of migraine is estimated at 10–12%. Clinical data and experience to date have demonstrated that botulinum toxin may be an effective prophylactic treatment for chronic headache types. It has been used in neurology for the treatment of dystonia and blepharospasm. Now it has been approved to treat chronic migraine and has been shown to confer significant benefit in refractory cases. Based on clinical experience botulinum toxin has also been tried in other headache disorders. While it is intuitively attractive to think that due to its effect on pain by sensory modulation, there may also be efficacy in its use in chronic tension-type headache and cluster headache, so far, there is little evidence to support this. Botulinum toxin is effective in pain control through its interaction with the SNARE complex, which inhibits the release of neurotransmitters, such as glutamate, substance P and calcitonin gene-related peptide. OnabotulinumtoxinA is effective not only in headache frequency and pain intensity but in other parameters, including quality of life. MDPI 2022-09-05 /pmc/articles/PMC9501363/ /pubmed/36136557 http://dx.doi.org/10.3390/toxins14090619 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kępczyńska, Katarzyna
Domitrz, Izabela
Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
title Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
title_full Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
title_fullStr Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
title_full_unstemmed Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
title_short Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
title_sort botulinum toxin—a current place in the treatment of chronic migraine and other primary headaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501363/
https://www.ncbi.nlm.nih.gov/pubmed/36136557
http://dx.doi.org/10.3390/toxins14090619
work_keys_str_mv AT kepczynskakatarzyna botulinumtoxinacurrentplaceinthetreatmentofchronicmigraineandotherprimaryheadaches
AT domitrzizabela botulinumtoxinacurrentplaceinthetreatmentofchronicmigraineandotherprimaryheadaches